1 Result

People

  1. Bisogna-Rendleman
    Bisogna-Rendleman
  2. Joseph
    Joseph
  3. Kauff
    Kauff
  4. Levine
    Levine
  5. Offit
    Offit
  6. Olson
    Olson
  7. Orlow
    Orlow
  8. Pike
    Pike
  9. Robson
    Robson

Groups

  1. Breast Medicine Service (1)
  2. Center for Pancreatic Cancer Research (1)
  3. Clinical Genetics Service (1)
  4. Department of Medicine (1)
  5. Epidemiology Service (1)
  6. Epidemiology and Biostatistics (1)
  7. GSK Faculty (1)
  8. Population Sciences Research Program (1)
  9. Solid Tumor Oncology Division (1)
  10. Surgery (1)
  1. "clinical outcome"
  2. "Epidemiology and Biostatistics"
  3. "Surgery"
  4. "Douglas Levine"
Formats
  1. Journal Article (1)
Groups
  1. Breast Medicine Service (1)
  2. Center for Pancreatic Cancer Research (1)
  3. Clinical Genetics Service (1)
  4. Department of Medicine (1)
  5. Epidemiology Service (1)
  6. Epidemiology and Biostatistics (1)

More Groups

People
  1. Douglas Levine (1)
  2. Irene Orlow (1)
  3. Kenneth Offit (1)
  4. Malcolm Pike (1)
  5. Maria Bisogna-Rendleman (1)
  6. Mark Robson (1)

More People

Years
  1. 2016 (1)
Publications
  1. Gynecologic Oncology (1)
Publishers
  1. Elsevier Inc. (1)

Results (1)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
    Journal Article

    Ovarian Cancer Association Consortium; Breast Cancer Association Consortium; Hollestelle, A.; Van Der Baan, F. H.; Berchuck, A.; Johnatty, S. E.; Aben, K. K.; Agnarsson, B. A.; Aittomäki, K.; Alducci, E.; more...
    Gynecologic Oncology (2016)

    Fulltext@MSK | Save